CSL R&D Head Touts Cost-Effectiveness of Hemophilia Gene Therapy Hemgenix

Bill Mezzanotte, Executive Vice President, Head of R&D and Chief Medical Officer, CSL (Courtesy of CSL Behring) After bagging the nod of the US FDA last November, the world’s first hemophilia B gene therapy, developed by CSL Behring, snared conditional...read more